Overview

An Efficacy and Safety Study of AZD4831 (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

Status:
Not yet recruiting
Trial end date:
2024-04-12
Target enrollment:
Participant gender:
Summary
This is a research study to evaluate the efficacy and safety of the investigational drug AZD4831 in adult participants with chronic obstructive pulmonary disease.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca